

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 05-403	Serial No. To Be Assigned 10/536939
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Christophe Revirron	
		Filing Date: Herewith	Group: To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
---------------------	-----------------	------	------	-------	----------	----------------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
A1	WO 94/06429 A	March 31, 1994	PCT			x

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

A2	XP002240083, "Xyzal (Levocetirizine) launched in England for Allergic Rhinitis", 2001 , www.pslgroup.com/dg/207766.htm .	
A3	XP002240084, "Germany Approves Antihistamines Xyzal", 2001 , www.pslgroup.com/dg/lefc66.htm .	
A4	Gensthaler, B. M., "Levocetirizine: R-enantiomer against allergies", <i>Pharmazeutische Zeitung</i> , 2001 , Vol. 146, No. 7, pp. 35-36.	
A5	Grant et al., "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.", <i>Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology</i> , 2002 , Vol. 88, No. 2, pp. 190-197.	
A6	Gandon et al., "Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.", <i>British Journal of Clinical Pharmacology</i> , 2002 , Vol. 54, No. 1, pp. 51-58.	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.